Aldo-keto reductase family 1 (AKR1) enzymes play a crucial role in diabetic complications. Since type 2 diabetes (T2D) is associated with cancer progression, we investigated the impact of diabetes onAKR1gene expression in the context of prostate cancer (PCa) development. In this study, we analyzed benign (BEN) prostate and PCa tissue of patients with and without T2D. Furthermore, to replicate hyperglycemia in vitro, we treated the prostate adenocarcinoma cell line PC3 with increasing glucose concentrations. Gene expression was quantified using real-time qPCR. In the prostate tissue of patients with T2D,AKR1C1andAKR1C2transcripts were higher compared to samples of patients without diabetes. In PC3 cells, high glucose treatment induced the gene expression levels ofAKR1C1,C2,andC3. Furthermore, both in human tissue and in PC3 cells, the transcript levels ofAKR1C1, C2,andC3showed positive associations with oncogenes, which are involved in proliferation processes and HIF1 alpha and NF kappa B pathways. These results indicate that in the prostate glands of patients with T2D, hyperglycemia could play a pivotal role by inducing the expression ofAKR1C1, C2,andC3. The higher transcript level ofAKR1Cwas furthermore associated with upregulated HIF1 alpha and NF kappa B pathways, which are major drivers of PCa carcinogenesis.